๐Ÿ’€ CASE STUDY ยท STARTUP
๐Ÿงช

Why Did Zymergen Fail?

The $3B Synthetic Biology IPO With Zero Market

2021YEAR
โ˜ ๏ธ STARTUPCAUSE
๐Ÿ’ธ $3B IPO valuation; sold for $300M scraps within a yearTHE BURN

๐Ÿ“œ What Happened

Zymergen promised to use bio-engineered microbes to brew new revolutionary materials from scratch, backed by SoftBank's Vision Fund. In April 2021, it went public with a $3 billion valuation, highlighting its flagship optical film Hyaline for foldable smartphone screens. Just three months later, the company stunned Wall Street by announcing that Hyaline had technical flaws that made it unusable for smartphone manufacturers, and that commercial pipeline revenue for the next two years would be zero. CEO Josh Hoffman was ousted, shares crashed 76 percent in a single morning, and rival Ginkgo Bioworks bought Zymergen for stock pennies.

โ˜ ๏ธ The Fatal Mistake

Going public on the commercial promise of a single material that had never completed customer qualification testing.

๐Ÿง  The Lesson (Free for You)

Lab prototypes are not commercial products. Until enterprise customers validate that your material integrates into their manufacturing lines, forecasting revenue is pure fantasy.

The Antidote Book

The Lean Startup cover
The Lean Startup Eric Ries ยท Business & Startups ยท 6 lessons

A startup's only job is learning what customers actually want - faster than the money runs out....

๐Ÿ“– OPEN THE FULL INTERACTIVE BREAKDOWN โ†’
๐Ÿ’€ EXPLORE ALL 530 FAILURE CASE STUDIES

Searchable, filterable, simple to read - they paid billions; you get the lesson.